Quick Answer
Neumora Therapeutics, Inc. reported Stockholders Equity of $103.87 million for the year ending 2025.
- Neumora Therapeutics, Inc. showed a decrease of -63.8% in Stockholders Equity from 2024 to 2025.
- This data is from Neumora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$366.02 million | Q2 2022: -$394.71 million | Q3 2022: -$422.00 million | Q1 2023: -$477.92 million | Q2 2023: -$513.54 million | Q3 2023: $512.69 million | Q1 2024: $424.54 million | Q2 2024: $381.26 million | Q3 2024: $320.74 million | Q1 2025: $228.36 million | Q2 2025: $182.88 million | Q3 2025: $132.16 million.
- Over the full 5 years of available data (2021 to 2025), Neumora Therapeutics, Inc.'s Stockholders Equity has grown by 131.9%.
- Historical annual values: Fiscal year 2025: $103.87 million | Fiscal year 2024: $287.06 million | Fiscal year 2023: $469.08 million | Fiscal year 2022: -$446.85 million | Fiscal year 2021: -$325.22 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: